×

Clinical Trials

Here you'll find a complete list of current clinical trials near you.

Clinical Trials

Here you'll find a complete list of current clinical trials near you.

Northeast

Massachusetts

Hospital Study Title Trial Link Status

Beth Israel Deaconess Medical Center, Boston, MA

Dana Farber Cancer Institute, Boston, MA

A Phase 2 Multicohort Study of Nivolumab in Combination with Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone Sensitive Prostate Cancer Patients with DNA Damage Repair Defects or Inflamed Tumors

NCT04126070

Recruiting

New Jersey

Hospital Study Title Trial Link Status

Memorial Sloan Kettering Cancer Center Basking Ridge, Basking Ridge, NJ

Memorial Sloan Kettering Cancer Center Bergen, Montvale, NJ

A Phase Ib/II Study of Intermittent Talazoparib Plus Temozolomide in Subjects with Metastatic Castration Resistant Prostate Cancer and No Mutations in DNA Damage Repair

NCT04019327

Recruiting

Memorial Sloan Kettering Cancer Center Basking Ridge, Basking Ridge, NJ

Memorial Sloan Kettering Cancer Center Bergen, Montvale, NJ

A Phase II Study of Olaparib and Durvalumab in Men with Castration Sensitive Biochemically Recurrent Non Metastatic Prostate Cancer Harboring Mutations in DNA Damage Repair

NCT03810105

Recruiting

Memorial Sloan Kettering Cancer Center Basking Ridge, Basking Ridge, NJ

Memorial Sloan Kettering Cancer Center Bergen, Montvale, NJ

Memorial Sloan Kettering Cancer Center Monmouth, Middletown, NJ

SAABR: Single Arm Phase II Study of Abiraterone + Atezolizumab + GnRH analog and Stereotactic Body Radiotherapy (SBRT) to the Prostate in Men with Newly Diagnosed Hormone-sensitive Metastatic Prostate Cancer

NCT04262154

Recruiting

New York

Hospital Study Title Trial Link Status

Columbia University Medical Center, New York, NY

A Multicenter, Open-Label, Parallel, Phase 1b/2a Study of PLX2853 in Combination with Abiraterone Acetate and Prednisone and Phase 1b/2a Study of PLX2853 in Combination with Olaparib in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT04556617

Recruiting

Memorial Sloan Kettering Cancer Center, New York, NY

Memorial Sloan Kettering Cancer Center Commack, Commack, NY

Memorial Sloan Kettering Cancer Center Westchester, Harrison, NY

A Phase II Study of Olaparib and Durvalumab in Men with Castration Sensitive Biochemically Recurrent Non Metastatic Prostate Cancer Harboring Mutations in DNA Damage Repair

NCT03810105

Recruiting

Weill Cornell Medical College, New York, NY

Phase II Trial of Rucaparib in Patients with Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH)

NCT03413995

Recruiting

Memorial Sloan Kettering Cancer Center, New York, NY

Memorial Sloan Kettering Cancer Center Commack, Commack, NY

Memorial Sloan Kettering Cancer Center Westchester, Harrison, NY

Memorial Sloan Kettering Cancer Center Nassau, Uniondale, NY

A Phase Ib/II Study of Intermittent Talazoparib Plus Temozolomide in Subjects with Metastatic Castration Resistant Prostate Cancer and No Mutations in DNA Damage Repair

NCT04019327

Recruiting

Weill Cornell Medical College, New York, NY

A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects

NCT03012321

Recruiting

Columbia University Medical Center, New York, NY

Memorial Sloan Kettering Cancer Center, New York, NY

Memorial Sloan Kettering Cancer Center Commack, Commack, NY

Memorial Sloan Kettering Cancer Center Westchester, Harrison, NY

Memorial Sloan Kettering Cancer Center Nassau, Uniondale, NY

SAABR: Single Arm Phase II Study of Abiraterone + Atezolizumab + GnRH analog and Stereotactic Body Radiotherapy (SBRT) to the Prostate in Men with Newly Diagnosed Hormone-sensitive Metastatic Prostate Cancer

NCT04262154

Recruiting

Pennsylvania

Hospital Study Title Trial Link Status

Allegheny Cancer Center, Pittsburgh, Pennsylvania

Thomas Jefferson University, Philadelphia, Pennsylvania

Phase II Study of Olaparib in Men with High-Risk Biochemically-Recurrent Prostate Cancer After Radical Prostatectomy, with Integrated Biomarker Analysis

NCT03047135

Recruiting

Midwest

Illinois

Hospital Study Title Trial Link Status

University of Chicago, Chicago, IL

A Multicenter, Open-Label, Parallel, Phase 1b/2a Study of PLX2853 in Combination with Abiraterone Acetate and Prednisone and Phase 1b/2a Study of PLX2853 in Combination with Olaparib in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT04556617

Recruiting

University of Illinois at Chicago, Chicago, IL

A Phase II Study of Olaparib and Durvalumab in Men with Castration Sensitive Biochemically Recurrent Non Metastatic Prostate Cancer Harboring Mutations in DNA Damage Repair

NCT03810105

Recruiting

Kellogg Cancer Center- NorthShore University, Evanston, IL

Northwestern Medicine, Chicago, IL

Rush University Cancer Center, IL

University of Chicago, Chicago, IL

A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects

NCT03012321

Recruiting

Indiana

Hospital Study Title Trial Link Status

Indiana University/ Melvin and Bren Simon Cancer Center, Indianapolis, IN

A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects

NCT03012321

Recruiting

Michigan

Hospital Study Title Trial Link Status

Karmanos Cancer Institute, Detroit, MI

A Multicenter, Open-Label, Parallel, Phase 1b/2a Study of PLX2853 in Combination with Abiraterone Acetate and Prednisone and Phase 1b/2a Study of PLX2853 in Combination with Olaparib in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT04556617

Recruiting

Karmanos Cancer Institute, Detroit, MI

A Phase II Study of Olaparib and Durvalumab in Men with Castration Sensitive Biochemically Recurrent Non Metastatic Prostate Cancer Harboring Mutations in DNA Damage Repair

NCT03810105

Recruiting

University of Michigan Health System, Ann Arbor, MI

A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects

NCT03012321

Recruiting

Minnesota

Hospital Study Title Trial Link Status

Mayo Clinic, Rochester, MN

A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects

NCT03012321

Recruiting

Missouri

Hospital Study Title Trial Link Status

Washington University School of Medicine, Saint Louis, MO

A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects

NCT03012321

Recruiting

Nebraska

Hospital Study Title Trial Link Status

University of Nebraska Medical Center, Omaha, NE

Phase II Study of Olaparib in Men with High-Risk Biochemically-Recurrent Prostate Cancer After Radical Prostatectomy, with Integrated Biomarker Analysis

NCT03047135

Recruiting

Wisconsin

Hospital Study Title Trial Link Status

University of Wisconsin, Madison, WI

A Multicenter, Open-Label, Parallel, Phase 1b/2a Study of PLX2853 in Combination with Abiraterone Acetate and Prednisone and Phase 1b/2a Study of PLX2853 in Combination with Olaparib in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT04556617

Recruiting

University of Wisconsin, Madison, WI

A Phase Ib/II Study of Intermittent Talazoparib Plus Temozolomide in Subjects with Metastatic Castration Resistant Prostate Cancer and No Mutations in DNA Damage Repair

NCT04019327

Recruiting

West

California

Hospital Study Title Trial Link Status

City of Hope Comprehensive Cancer Center, Duarte, CA

A Phase II Study of Olaparib and Durvalumab in Men with Castration Sensitive Biochemically Recurrent Non Metastatic Prostate Cancer Harboring Mutations in DNA Damage Repair

NCT03810105

Recruiting

University of California Los Angeles, Los Angeles, CA

A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects

NCT03012321

Recruiting

Utah

Hospital Study Title Trial Link Status

Huntsman Cancer Institute – University of Utah, Salt Lake City, UT

A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects

NCT03012321

Recruiting

Washington State

Hospital Study Title Trial Link Status

Fred Hutchinson Cancer Research Center, Seattle, WA

Durvalumab (MEDI4736) and Olaparib (AZD2281) for treatment of biochemically recurrent prostate cancer in men predicted to have a high neoantigen load: a pilot study

NCT04336943

Recruiting

South

Florida

Hospital Study Title Trial Link Status

H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects

NCT03012321

Recruiting

Maryland

Hospital Study Title Trial Link Status

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

Phase II Study of Olaparib in Men with High-Risk Biochemically-Recurrent Prostate Cancer After Radical Prostatectomy, with Integrated Biomarker Analysis

NCT03047135

Recruiting

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

Phase II Trial of Rucaparib in Patients with Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH)

NCT03413995

Recruiting

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects

NCT03012321

Recruiting

North Carolina

Hospital Study Title Trial Link Status

University of North Carolina at Chapel Hill, Chapel Hill, NC

A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects

NCT03012321

Recruiting

South Carolina

Hospital Study Title Trial Link Status

Carolina Urologic Research Center, Myrtle Beach, SC

A Multicenter, Open-Label, Parallel, Phase 1b/2a Study of PLX2853 in Combination with Abiraterone Acetate and Prednisone and Phase 1b/2a Study of PLX2853 in Combination with Olaparib in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT04556617

Recruiting

Tennessee

Hospital Study Title Trial Link Status

Tennessee Oncology/ Sarah Cannon, Nashville, TN

A Multicenter, Open-Label, Parallel, Phase 1b/2a Study of PLX2853 in Combination with Abiraterone Acetate and Prednisone and Phase 1b/2a Study of PLX2853 in Combination with Olaparib in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT04556617

Recruiting

Virginia

Hospital Study Title Trial Link Status

Virginia Cancer Specialists, Fairfax, VA

A Multicenter, Open-Label, Parallel, Phase 1b/2a Study of PLX2853 in Combination with Abiraterone Acetate and Prednisone and Phase 1b/2a Study of PLX2853 in Combination with Olaparib in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT04556617

Recruiting

University of Virginia, Charlottesville, VA

A Phase Ib/II Study of Intermittent Talazoparib Plus Temozolomide in Subjects with Metastatic Castration Resistant Prostate Cancer and No Mutations in DNA Damage Repair

NCT04019327

Recruiting

University of Virginia, Charlottesville, VA

A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects

NCT03012321

Recruiting